Marksans Pharma (BOM:524404) Margin of Safety % (DCF Earnings Based): -23.65% (As of Jul. 01, 2026)


BOM:524404 Marksans Pharma Ltd BOM:524404
85 GF Score
Price ₹272.05
GF Value ₹227.74
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is Marksans Pharma Margin of Safety % (DCF Earnings Based)?

Marksans Pharma BOM:524404 +3.34% 85 Margin of Safety % (DCF Earnings Based) is -23.65% as of Jul. 01, 2026. GuruFocus rates BOM:524404 with a GF Score™ of 85/100 and a GF Value™ of ₹227.74 (Modestly Overvalued). The stock has 5 warning signs investors should review.

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

As of today (2026-07-01), Marksans Pharma's Predictability Rank is 4-Stars. Marksans Pharma's intrinsic value calculated from the Discounted Earnings model is ₹220.02 and current share price is ₹272.05. Consequently,

Marksans Pharma's Margin of Safety % (DCF Earnings Based) using Discounted Earnings model is -23.65%.

BOM:524404 vs LLY, JNJ, ABBV: Margin of Safety % (DCF Earnings Based) Comparison

For the Drug Manufacturers - General subindustry, Marksans Pharma's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Marksans Pharma Margin of Safety % (DCF Earnings Based) vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Marksans Pharma's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Marksans Pharma's Margin of Safety % (DCF Earnings Based) falls into.


BOM:524404
85GF Score
Marksans Pharma Ltd BOM:524404
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Marksans Pharma Margin of Safety % (DCF Earnings Based) Calculation

Marksans Pharma's Margin of Safety % (DCF Earnings Based) for today is calculated as

Margin of Safety % (DCF Earnings Based)=(Intrinsic Value: DCF (Earnings Based)-Current Price)/Intrinsic Value: DCF (Earnings Based)
=(220.02-272.05)/220.02
=-23.65 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The intrinsic value is calculated from the Discounted Earnings model with default parameters. The calculation method is the same as Discounted Cash Flow model except earnings are used in the calculation instead of free cash flow.

What does a Margin of Safety % (DCF Earnings Based) of -23.65% mean?
Marksans Pharma (BOM:524404) has a Margin of Safety % (DCF Earnings Based) of -23.65% as of Jul. 01, 2026. Margin of Safety % (DCF Earnings Based) is the percent difference between the current price and the intrinsic DCF Earnings price. View historical data on Marksans Pharma.
Is Marksans Pharma's Margin of Safety % (DCF Earnings Based) too high?
Marksans Pharma's current Margin of Safety % (DCF Earnings Based) is -23.65%. Overall, Marksans Pharma has a GF Score™ of 85/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Marksans Pharma's Margin of Safety % (DCF Earnings Based) compare to LLY and JNJ?
Marksans Pharma's Margin of Safety % (DCF Earnings Based) of -23.65% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Margin of Safety % (DCF Earnings Based) for a Drug Manufacturers company?
A good Margin of Safety % (DCF Earnings Based) depends on the Drug Manufacturers industry context. However, Margin of Safety % (DCF Earnings Based) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Margin of Safety % (DCF Earnings Based) mean?
A high Margin of Safety % (DCF Earnings Based) can signal that a stock is expensive relative to its fundamentals. Margin of Safety % (DCF Earnings Based) is the percent difference between the current price and the intrinsic DCF Earnings price. View historical data on Marksans Pharma. Marksans Pharma's current Margin of Safety % (DCF Earnings Based) is -23.65%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Marksans Pharma stock overvalued right now?
Based on GuruFocus' analysis, Marksans Pharma (BOM:524404) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹227.74, compared to a current price of ₹272.05 — trading 19.5% above its estimated fair value. The current Margin of Safety % (DCF Earnings Based) is -23.65%. Marksans Pharma's overall GF Score™ is 85/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Margin of Safety % (DCF Earnings Based) calculated?
Margin of Safety % (DCF Earnings Based) is calculated from a company's financial statements. For Marksans Pharma (BOM:524404), the current Margin of Safety % (DCF Earnings Based) is -23.65% as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Marksans Pharma (BOM:524404) Overvalued in 2026?

Based on GuruFocus' analysis, Marksans Pharma stock appears to be overvalued. The current stock price of ₹272.05 is trading 19.5% above its estimated GF Value™ of ₹227.74. GuruFocus considers Marksans Pharma to be Modestly Overvalued.

Key valuation signals for BOM:524404:

  • Margin of Safety % (DCF Earnings Based): -23.65%
  • GF Value™: ₹227.74 vs. price of ₹272.05 (19.5% above fair value)
  • GF Score™: 85/100 with 5 warning signs

No single metric tells the full story. See the BOM:524404 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Marksans Pharma Business Description

Other Exchanges MARKSANS:India
Address Veera Desai Extension Road, 11th Floor, Grandeur, Opposite Gundecha Symphony, Oshiwara, Andheri (West), Mumbai, MH, IND, 400053
Marksans Pharma Ltd is a pharmaceutical company. The company is engaged in the research, manufacturing, and marketing of pharmaceutical formulations. It manufactures analgesics, gastroenterology, anti-diabetic, cardiovascular, pain management, gynecology, gastrointestinal, and oncologic drugs as well as antibiotics and antiallergic medications. Geographically, the majority of its revenue is generated from the United States and North America, followed by Europe and the UK, Australia and New Zealand, and the Rest of the World.
85GF Score

Get the complete analysis for BOM:524404

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹272.05
Price
₹227.74
GF Value